Anti-VGLUT3 antibody [N34/34]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

VGLUT3 also known as Vesicular Glutamate Transporter 3 or SLC17A8 functions as a transporter responsible for loading the neurotransmitter glutamate into synaptic vesicles in neurons. It has a molecular mass of approximately 65 kDa. VGLUT3 expression occurs in specific regions of the central nervous system such as the hippocampus and striatum as well as in sensory regions like the cochlea. This transporter lacks the abundance compared to other VGLUTs making its presence more strategically targeted in its roles.

Biological function summary

VGLUT3 modulates neurotransmitter signaling by facilitating glutamate release in both excitatory and modulatory circuits. It operates not strictly as part of a homomeric complex but interacts closely with other synaptic proteins to regulate neurotransmission. VGLUT3 presence in serotonin and dopamine neurons indicates its role in modulating their transmission suggesting a diverse function beyond typical excitatory neurotransmitter release. This transporter's activity influences synaptic plasticity and firing patterns vital for maintaining neural circuit balance.

Pathways

VGLUT3 integrates into the glutamatergic transmission pathway and the modulation of dopaminergic and serotonergic pathways. It works alongside VGLUT1 and VGLUT2 though each has a different regional brain expression allowing diverse neurotransmitter interactions in neural signaling. The transporter interacts with synaptic machinery influencing pathways responsible for synaptic vesicle recycling and neurotransmitter homeostasis ensuring effective transmission functions in responsive neurons.

Associated diseases and disorders

VGLUT3 influences conditions such as epilepsy and schizophrenia. Its dysfunction can lead to improper glutamate levels in the synaptic cleft disrupting neural excitability and causing conditions like seizures or altered neuropsychiatric states. VGLUT3 shares connections with transport proteins like SLC1A1 affecting glutamate transport across membranes. Understanding these associations aids in therapeutic target development where modulating VGLUT3 function could address glutamatergic dysregulation contributing to these disorders.